CD19 and leukemia: Another bispecific CAR, the CD19/CD22 bivalent CAR, was generated by Qin et al. and tested in a “spike-in” leukaemia relapse model utilising NALM6 cells and CD19−/CD22− loss variants edited by CRISPR-Cas9 technology [57].